- Home
- CHRS vs EARN Comparison
CHRS vs EARN Comparison
Compare CHRS & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EARN
- Stock Information
- Founded
- CHRS 2010
- EARN 2012
- Country
- CHRS United States
- EARN United States
- Employees
- CHRS N/A
- EARN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EARN Real Estate Investment Trusts
- Sector
- CHRS Health Care
- EARN Real Estate
- Exchange
- CHRS Nasdaq
- EARN Nasdaq
- Market Cap
- CHRS 191.3M
- EARN 187.6M
- IPO Year
- CHRS 2014
- EARN 2013
- Fundamental
- Price
- CHRS $1.24
- EARN $6.62
- Analyst Decision
- CHRS Strong Buy
- EARN Hold
- Analyst Count
- CHRS 4
- EARN 1
- Target Price
- CHRS $5.38
- EARN N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- EARN 495.3K
- Earning Date
- CHRS 03-12-2025
- EARN 03-05-2025
- Dividend Yield
- CHRS N/A
- EARN 14.43%
- EPS Growth
- CHRS N/A
- EARN 277.67
- EPS
- CHRS N/A
- EARN 1.02
- Revenue
- CHRS $304,340,000.00
- EARN N/A
- Revenue This Year
- CHRS $2.47
- EARN N/A
- Revenue Next Year
- CHRS N/A
- EARN $89.08
- P/E Ratio
- CHRS N/A
- EARN $6.49
- Revenue Growth
- CHRS 44.19
- EARN N/A
- 52 Week Low
- CHRS $0.66
- EARN $5.54
- 52 Week High
- CHRS $2.87
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- EARN 50.57
- Support Level
- CHRS $1.38
- EARN $6.30
- Resistance Level
- CHRS $1.45
- EARN $6.79
- Average True Range (ATR)
- CHRS 0.13
- EARN 0.14
- MACD
- CHRS -0.04
- EARN 0.01
- Stochastic Oscillator
- CHRS 4.50
- EARN 57.14
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.